Histonics Series D Funding Raises $102M

With the goal of using ultrasonic pulses sent from outside the body to focus on liver tumours, Histosonics has received $102 million in fresh capital to assist with the platform’s commercial expansion and continued research.

The FDA granted de novo authorisation to the business’s histotripsy system in October. It uses sound waves to break apart and destroy tumour tissue, providing a non-invasive alternative to potentially harmful therapies for cancer like radiation, chemotherapy, and surgery.

According to Histosonics, the Series D funding will be utilised to promote commercial expansion in both the US and international markets and accelerate research on the Edison histotripsy platform. With a portion of the funds, the business also intends to start a prospective research assessing the technology in multimodal liver tumour treatment methods.

CEO Mike Blue stated: “This funding will accelerate key projects designed to enhance core technical capabilities impacting current and future platforms, and support collaboration with physicians and researchers studying innovative ways to use histotripsy’s unique mechanism of action,” CEO Mike Blue said in a Thursday statement.

He continued: “By pioneering a new category of medicine with histotripsy, HistoSonics is redefining liver tumor treatment and providing hope for millions of people worldwide who desperately need new options,” Blue added.